CGON Stock Summary and Trading Ideas (CG Oncology | NASDAQ:CGON)

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

CG Oncology trades on the NASDAQ stock market under the symbol CGON.

As of January 30, 2026, CGON stock price declined to $52.05 with 739,237 million shares trading.

CGON has a beta of 2.38, meaning it tends to be more sensitive to market movements. CGON has a correlation of 0.32 to the broad based SPY ETF.

CGON has a market cap of $4.30 billion. This is considered a Mid Cap stock.

Last quarter CG Oncology reported $2 million in Revenue and -$.57 earnings per share. This beat revenue expectation by $1 million and missed earnings estimates by -$.01.

The top ETF exchange traded funds that CGON belongs to (by Net Assets): XBI, VTI, IWM, VB, VBR.

CGON has outperformed the market in the last year with a return of +71.8%, while the SPY ETF gained +16.2%. In the last 3 month period, CGON beat the market returning +21.1%, while SPY returned +1.0%. However, in the most recent 2 weeks CGON has underperformed the stock market by returning -1.9%, while SPY returned 0.0%.

CGON support price is $51.26 and resistance is $55.59 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CGON shares will trade within this expected range on the day.